[Feasibility study: concurrent 13-cis-retinoic acid, alfa-2a interferon and radiotherapy in the treatment of 23 patients with advanced cervix uteri epidermoid carcinoma].
The important therapeutic activity of 13-cRA and IFN-alpha-2a in carcinoma of squamous cells, cervical, without previous treatment, is confirmed. An unexpected result was the early toxicity of the biologic agents on the colon mucosa when they are combined with radiotherapy.
Paredes Espinoza
M
M
Servicio de Medicina Interna del Hospital Civil de Guadalajara y Torre de Especialidades.
Delgadillo Madrueño
F
F
Paredes Casillas
P
P
Delgadillo Hernández
J J
JJ
Ayala Castellanos
M M
MM
Alvarez Márquez
V
V
Buenrostro Ahued
M A
MA
Arias Castro
G
G
D000328:Adult; D000368:Aged; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002588:Cesium Radioisotopes / Q000008:administration & dosage; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003106:Colon / Q000187:drug effects / Q000528:radiation effects; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use* / Q000633:toxicity; D007413:Intestinal Mucosa / Q000187:drug effects / Q000528:radiation effects; D015474:Isotretinoin / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D011994:Recombinant Proteins; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
D002588:Cesium Radioisotopes; D003037:Cobalt Radioisotopes; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015474:Isotretinoin
Estudio de factibilidad: ácido 13-cisretinoico, interferón alpha-2a y radioterapia concurrentes en el tratamiento de 23 pacientes con carcinoma epidermoide cervicouterino avanzado.